One reagent for two techniques: Compound [111In]1 provides a platform for sequential radionuclide and optical imaging of prostate cancer through targeting of the prostate-specific membrane antigen. Because the same subject can be dual-imaged after one injection of the agent, these findings support rapid clinical translation.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.